Radient Technologies Inc. Announces Participation in a Medical Cannabis Study Led by the University Health Network in Partnership with Shoppers Drug Mart

Nachrichtenquelle: globenewswire
17.07.2020, 13:30  |  167   |   |   

EDMONTON, Alberta, July 17, 2020 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), a manufacturer of high quality cannabinoid-based formulations and products, is pleased to announce that bioU products by Radient will be available to patients in the recently announced University Health Networks’ (“UHN”)  Medical Cannabis Real-World Evidence Study (“MC-RWE Study”) in partnership with Medical Cannabis by Shoppers.  The first-of-its-kind study will involve a nation-wide clinical trial to examine the effects of medical cannabis on pain, sleep and anxiety issues.

Radient developed the bioU brand exclusively for Medical Cannabis by Shoppers and the products have been formulated to meet the highest levels of quality, consistency, and stability.  All three oral spray formulations currently available on the Medical Cannabis by Shoppers site will be available to patients enrolled in the MC-RWE Study, providing patients with a variety of options in THC and CBD products in a convenient and standard dose format.  As part of the study, all bioU products have undergone additional testing, with results registered on TruTrace Technologies software platform and integrated with the Medical Cannabis by Shoppers.

“Radient strongly believes that consistency, safety and standardization are key elements for all medical products, and are excited to partner with UHN, Shoppers and TruTrace on this groundbreaking study,” said Denis Taschuk, CEO of Radient Technologies.  “Providing patients and medical professionals with trusted products that deliver repeatable results is a crucial step in having cannabis incorporated into medical treatments and is at the heart of all Radient products.  Shoppers is creating a standard for medical cannabis, which along with the data from these clinical trials, will increase the confidence of both doctors and patients in using cannabis for medical purposes.”

About the UHN MC-RWE Study

Led by UHN's Dr. Hance Clarke, the observational study is targeting a minimum of 2,000 patients who will be followed over a 24-week period.  Enrolled patients will have access to certain fully verified products on the Medical Cannabis by Shoppers platform, which have been tested for detailed cannabinoid and terpene profiles.   Read more about the study here.

Seite 1 von 3
Radient Technologies Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Diesen Artikel teilen

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Radient Technologies Inc. Announces Participation in a Medical Cannabis Study Led by the University Health Network in Partnership with Shoppers Drug Mart EDMONTON, Alberta, July 17, 2020 (GLOBE NEWSWIRE) - Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), a manufacturer of high quality cannabinoid-based formulations and products, is pleased to announce that …

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel

Nachrichten zu den Werten

ZeitTitel
25.11.20